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Abstract 
Background: Granulosa cell tumors are rare sex cord stromal lesions that comprise 
approximately 3% of all ovarian neoplasms. The vast majority of granulosa cell tumors 
are considered indolent but in spite of aggressive management, delayed recurrence is of 
significant concern.  
Case Report: We describe a case involving a 67-year-old woman who presented with 
abdominal pain, bloody stools, and mild nausea. Following a CT scan of the abdomen 
and pelvis, a 19-cm pelvic mass was identified. Her prior medical history included a 
hysterectomy for uterine fibroids 40 years ago and a bilateral salpingo-oophorectomy for 
a presumed granulosa cell tumor 20 years ago. Final pathology revealed granulosa cell 
tumor with small bowel mesentery involvement. The patient underwent surgical 
resection and adjuvant chemotherapy; she is currently doing well.  
Conclusion: Granulosa cell tumors are considered to be of low malignant potential but 
they have the capacity to recur, even several years following initial patient management. 
This case exemplifies the disease’s capacity for prolonged recurrence and further 
accentuates the significance of long-term follow-up in these patients. 
 
Introduction 
Sex cord stromal tumors are relatively uncommon lesions that develop from the 
gonadal stroma. They constitute nearly 5–7% of all ovarian lesions and include granulosa 
stromal tumors, fibroma-thecoma, Sertoli-stromal cell tumors and steroid cell tumors [1, 
2]. Granulosa cell tumors are particularly rare, accounting for 2–3% of all ovarian 
malignancies [2].  
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Granulosa cell tumors have typically high survival rates, but they can be associated 
with extremely prolonged disease progression intervals; reported studies have described 
recurrences several years following initial treatment [3–5]. We report herein the history of 
a granulosa cell tumor patient who presumably exhibited recurrent disease 20 years 
following her oophorectomy for a hitherto, unrecognized granulosa cell tumor. 
Case Report 
A 67-year-old (gravida 4, para 4) woman complained of persistent lower abdominal pain and mild 
nausea in December 2009. She had been having bloody stools for several months with symptomatic 
anemia requiring blood transfusion prior to her referral to our practice. A palpable mass was found on 
exam and a CT scan of the abdomen and pelvis demonstrated a 17 × 19 × 13 cm pelvic mass, extending 
into the midline and right pelvis. There were also some solid, cystic components and a calcified center. 
Laboratory work-up revealed a CA-125 of 155 U/ml, a CEA of 2.2 ng/ml and serum inhibin B levels of 
1,394 pg/ml. The patient’s prior medical history was significant for hypertension, mild diabetes, 
herniorrhaphy in 2000 and 1987, an appendectomy and bilateral salpingo-oophorectomy in 1987 for a 
probable granulosa cell tumor, and total abdominal hysterectomy in 1969 for uterine fibroids. 
Colonoscopy and esophagogastroduodenoscopy procedures were then conducted, neither of which 
identified an intra-luminal colonic or gastric mass. Nevertheless, on the colonoscopy, there was some 
blood originating from the terminal ileum and small bowel. The differential diagnoses included 
primarily tumors of gastrointestinal origin such as GIST type tumor, retroperitoneal sarcoma or 
lymphoma. However, a CT-guided biopsy excluded lymphoma and stains were positive for inhibin, 
indicating a gynecologic neoplasm. 
At laparotomy, some cloudy ascites were encountered and the primary mass was found to originate 
from the mesentery of the ileum. There were tumor nodules studding the mesentery and peritoneum, 
primarily along the gutters and in the pelvis. At the root of the mesentery, the vasculature supplying the 
dominant mass was quite extensive. The bowel was divided proximally and distally to the mass and the 
involved mesentery was also resected en bloc (fig. 1). 
The remaining tumor nodules were removed via a combination of sharp dissection and cautery. 
Further, they were stripped out from the pelvis and bilaterally along the pelvic sidewall. The patient’s 
appendix, uterus, cervix, tubes and ovaries were surgically absent. There were some additional omental 
nodules identified and, thus, an infracolic omentectomy was performed. 
Final pathology revealed a malignant granulosa cell tumor involving the small bowel mesentery and 
ileum (fig. 2). Moreover, there were scattered tumor nodules identified within the mesentery, small 
bowel and omentum. Initially, a chemotherapy regimen comprising bleomycin, etoposide and platinum 
was considered, but because the patient had cardiac complications, she began 6 cycles of paclitaxel (175 
mg/m
2) and carboplatin (AUC = 6) in January 2010. In June 2010, her serum inhibin B levels declined 
to <10 pg/ml. Currently, she is doing well and receiving routine follow-up from her gynecologic 
oncologist. 
Conclusion 
Granulosa cell tumors are estrogenic ovarian tumors that have a propensity to develop 
in postmenopausal women [1]. Patients often present with intra-abdominal bleeding, 
abdominal distension or pain due to the tumor’s potentially considerable size. Moreover, 
50–60% of patients will develop either endometrial hyperplasia or a concurrent uterine 
cancer [3]. 
The majority of granulosa cell tumors are considered to be of low malignant potential. 
Disease stage appears to be the most important prognostic factor; most patients present 
with stage I tumors that coincide with 5-year survival rates (>90%), similar to borderline  
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ovarian tumors [1]. Conversely, large tumor size (>10 cm), high mitotic index and 
lymphatic invasion are associated with disease recurrence and a poor outcome [2, 6]. 
There are sufficient data to substantiate the risk for prolonged (e.g., up to 10 years) 
recurrence rates with granulosa cell tumors [2] and, in rare exceptions, extraordinarily 
protracted time frames [3–5]. Hasiakos et al. [3] described a granulosa cell tumor patient 
who had surgery alone and developed disease recurrence 25 years following the initial 
diagnosis. Moreover, Hines et al. [4] reported on a granulosa cell tumor patient who was 
treated with surgery and adjuvant bleomycin, etoposide and cisplatin chemotherapy; she 
exhibited progressive disease 37 years later. 
In the current study, our patient underwent a bilateral salpingo-oophorectomy in 1987 
for a probable granulosa cell tumor, eventually developing progressive disease in 2009. 
We suspect that the disease’s recurrence in the gastrointestinal tract may be attributed to 
transcoelomic spread, a process which has been implicated in ovarian and colonic 
malignancies [1, 7]. However, we recognize that without the pathology from the original 
surgical procedure, we cannot confirm that there is indeed a disease recurrence. One may 
also conjecture that the granulosa cell tumor developed from remaining fragments of 
ovarian tissue in situ subsequent to the patient’s bilateral salpingo-oophorectomy in 1987. 
Conservative surgery is the recommended treatment for granulosa cell tumors in 
patients who wish to retain their fertility status. In particular, a unilateral salpingo-
oophorectomy, staging and an endometrial biopsy to exclude uterine cancer may be 
adequate for stage I disease [1, 2]. Alternatively, in patients with more advanced stage 
disease, or when reproductive status is immaterial, standard management comprises total 
abdominal hysterectomy, bilateral salpingo-oophorectomy and surgical debulking. 
Chemotherapy consisting of bleomycin, etoposide and cisplatin has been extensively 
employed; more recently, taxanes in combination with platinum therapy have been 
evaluated to mitigate toxicity and improve progression-free survival rates [1, 3, 8]. 
Since long-term surveillance is essential for granulosa cell tumor patient management, 
tumor markers have been considered. Serum estradiol levels have not proven to be 
reliable, but elevated serum inhibin appears to correspond with increased granulosa cell 
tumor size [3, 9]. Elevated serum inhibin, a peptide hormone normally produced by 
ovarian granulosa cells, potentially coincides with increased granulosa cell tumor size 
[10]. 
Inhibin A and B are both significantly involved in pituitary follicle-stimulating 
hormone (FSH) secretion. However, inhibin A is primarily secreted by the corpus luteum 
and is associated with regulating FSH secretion during luteal-follicular transition; inhibin 
B is secreted in response to FSH
 and is
 a sensitive marker for follicular growth [9]. 
Clinically, a dramatic increase in serum inhibin B levels has been reported in granulosa 
cell tumor patients, whereas with serum inhibin A, the levels were far less pronounced 
[10]. Consequently, serial inhibin B measurement may be considered as a diagnostic 
marker for primary and recurrent disease. 
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Fig. 1. Gross photograph of the granulosa cell tumor. 
 
 
 
Fig. 2. Section of small-bowel mucosa and submucosal tumor mass (10×). 
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